Eledon Pharmaceuticals Inc ELDN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/24/24 EDT
2.82UNCH (UNCH)
Volume
187,435
52 week range
1.07 - 3.35
Loading...
  • Open2.88
  • Day High2.89
  • Day Low2.57
  • Prev Close2.89
  • 52 Week High3.35
  • 52 Week High Date05/20/24
  • 52 Week Low1.07
  • 52 Week Low Date11/09/23

Key Stats

  • Market Cap108.589M
  • Shares Out38.51M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.77
  • YTD % Change56.67

KEY STATS

  • Open2.88
  • Day High2.89
  • Day Low2.57
  • Prev Close2.89
  • 52 Week High3.35
  • 52 Week High Date05/20/24
  • 52 Week Low1.07
  • 52 Week Low Date11/09/23
  • Market Cap108.589M
  • Shares Out38.51M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.77
  • YTD % Change56.67

RATIOS/PROFITABILITY

  • EPS (TTM)-1.40
  • P/E (TTM)-2.01
  • Fwd P/E (NTM)-2.53
  • EBITDA (TTM)-42.759M
  • ROE (TTM)-53.27%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Eledon Pharmaceuticals Inc

 

Profile

MORE
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell...
Keith Katkin CPA
Independent Chairman of the Board
David-Alexandre Gros M.D.
Chief Executive Officer, Director
Steven Perrin Ph.D.
President, Chief Scientific Officer, Director
Paul Little
Chief Financial Officer
Address
19800 MACARTHUR BLVD., SUITE 250
Irvine, CA
92612
United States

Top Peers

SYMBOLLASTCHG%CHG
CTXR
Citius Pharmaceuticals Inc
0.66UNCHUNCH
NVCT
Nuvectis Pharma Inc
6.21UNCHUNCH
IMUX
Immunic Inc
1.25UNCHUNCH
VTGN
Vistagen Therapeutics Inc
4.08UNCHUNCH
VOR
Vor Biopharma Inc
1.55UNCHUNCH